替奈普酶溶栓治疗急性心肌梗死后颅内出血的风险因素与预测模型
结果显示收缩压升高、年龄增大、女性、低体重及替奈普酶剂量增加均与颅内出血风险升高相关。替奈普酶减量及溶栓前收缩压优化是潜在可干预策略。
要点
- 替奈普酶溶栓前应积极控制收缩压,尤其超过160 mmHg时颅内出血风险加速升高。
- 高龄患者使用替奈普酶时,年龄-剂量交互作用显著,减量可能降低颅内出血风险。
- 女性、低体重患者颅内出血风险更高,溶栓决策时需综合评估。
核心结论
- 替奈普酶剂量在高龄患者中下调以及溶栓前收缩压优化是降低颅内出血的潜在可调整策略。
研究设计与样本
- 纳入试验均采用体重调整替奈普酶方案,并统一排除收缩压大于180/110 mmHg的患者。
- 采用logistic回归模型评估风险因素,并构建列线图用于个体风险预测。
主要发现
- 收缩压超过160 mmHg后颅内出血风险加速升高。
- 随替奈普酶剂量增加,年龄相关的颅内出血风险升高更明显,30 mg时风险每年增加约1%,50 mg时接近每年7%。
- 多变量模型纳入年龄、性别、收缩压、体重、替奈普酶剂量及年龄-剂量交互项,C指数为0.718(95%CI 0.68-0.76)。
关键数值与推荐
- 替奈普酶溶栓前收缩压排除标准为大于180/110 mmHg。
- 年龄-剂量交互:30 mg替奈普酶时颅内出血风险每年增加约1%,50 mg时接近每年7%。
临床怎么用
- 高龄STEMI患者考虑替奈普酶溶栓时,可评估减量以降低颅内出血风险。
- 溶栓前应优先控制收缩压,避免血压过高尤其是超过160 mmHg时颅内出血风险加速上升。
- 女性或低体重患者溶栓前应更谨慎评估颅内出血风险。
局限性
- 本研究为汇总临床试验数据的事后分析,存在残余混杂可能。
- 颅内出血事件数较少,可能影响部分亚组估计的稳定性。
- 列线图预测模型需要在前瞻性队列中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Intracranial haemorrhage (ICH) is a significant complication of fibrinolytic therapy for ST-elevation myocardial infarction (STEMI). The risk factors for ICH following tenecteplase (TNK) administration were evaluated, and a clinical risk prediction tool was developed. METHODS: A pooled individual patient data analysis from STEMI patients who received weight-adjusted TNK with a consistent blood pressure exclusion criterion of >180/110 mmHg in six randomized controlled trials (ASSENT-2, ASSENT-3, ASSENT-3 PLUS, ASSENT-4 PCI, STREAM, STREAM-2) was undertaken. Logistic regression was used to model risk factors, and a nomogram was developed for individual risk prediction. RESULTS: Among 15 954 patients, 169 developed ICH. Above a systolic blood pressure (SBP) threshold of 110 mmHg, each 1 mmHg increase conferred a 2% relative increase in ICH risk [adjusted odds ratio (aOR) 1.02, 95% confidence interval (CI) 1.01-1.03; P < .0001]; risk accelerated sharply beyond 160 mmHg. With increasing dose, the likelihood of ICH increased with age, rising from 1% per year (30 mg TNK) to nearly 7% per year with 50 mg. The multivariable model incorporating age, sex, SBP, body weight, and TNK dose with the age-dose interaction demonstrated good discrimination (C index 0.718; 95% CI 0.68-0.76). Female sex conferred a 49% increased ICH risk (aOR 1.49, 95% CI 1.06-2.11; P = .023), and each 5 kg decrease in body weight was associated with 16% increased odds of ICH (aOR 1.16, 95% CI 1.03-1.30; P = .014). CONCLUSIONS: Dose reduction of TNK in older patients and SBP optimization before fibrinolytic administration represent modifiable strategies to potentially reduce ICH.
引用
- Armstrong, Danays, Westerhout, et al. Intracranial haemorrhage following tenecteplase fibrinolysis for acute myocardial infarction. Eur Heart J. 2026. PMID: 42766418. doi:10.1093/eurheartj/ehag754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。